These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27187295)

  • 1. Utility of Cancer Value Frameworks for Patients, Payers, and Physicians.
    Chandra A; Shafrin J; Dhawan R
    JAMA; 2016 May; 315(19):2069-70. PubMed ID: 27187295
    [No Abstract]   [Full Text] [Related]  

  • 2. Reimbursement issues facing patients, providers, and payers.
    Antman K
    Cancer; 1993 Nov; 72(9 Suppl):2842-5. PubMed ID: 8402516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three questions about costs and cancer clinical trials.
    Chirikos TN
    Cancer Control; 2003; 10(1):71-8. PubMed ID: 12598857
    [No Abstract]   [Full Text] [Related]  

  • 4. Addressing the Financial Burden of Cancer Treatment: From Copay to Can't Pay.
    Shankaran V; Ramsey S
    JAMA Oncol; 2015 Jun; 1(3):273-4. PubMed ID: 26181165
    [No Abstract]   [Full Text] [Related]  

  • 5. What's cost-effective in cancer care?
    Cancer Discov; 2011 Nov; 1(6):OF1-2. PubMed ID: 22586658
    [No Abstract]   [Full Text] [Related]  

  • 6. How the Affordable Care Act Has Affected Cancer Care in the United States: Has Value for Cancer Patients Improved?
    Schleicher SM; Wood NM; Lee S; Feeley TW
    Oncology (Williston Park); 2016 May; 30(5):468-74. PubMed ID: 27188679
    [No Abstract]   [Full Text] [Related]  

  • 7. Reimbursement issues in clinical oncology.
    Vogelzang NJ; Chabner BA; Periman P; Ohrt DK; McCann BC; Burns JM; Bayer R
    Semin Oncol; 1988 Dec; 15(6 Suppl 6):34-43. PubMed ID: 3061015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of accountable care organizations on oncology practice.
    Shulman LN
    Am Soc Clin Oncol Educ Book; 2014; ():e468-71. PubMed ID: 24857141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers to clinical trial enrollment: are state mandates the solution?
    Hillner BE
    J Natl Cancer Inst; 2004 Jul; 96(14):1048-9. PubMed ID: 15265958
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provider Perspective on the Payer Perspective: What's in It for Me?
    Stella PJ; Harrison KA
    J Oncol Pract; 2015 May; 11(3):182-4. PubMed ID: 25804990
    [No Abstract]   [Full Text] [Related]  

  • 12. Reimbursement for patient and family meetings and the costs of care at the end of life.
    Hilty SA
    JAMA; 2008 Nov; 300(18):2119-20; author reply 2120. PubMed ID: 19001622
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative effectiveness research in oncology: the need for clarity, transparency and vision.
    Lyman GH
    Cancer Invest; 2009 Jul; 27(6):593-7. PubMed ID: 19557579
    [No Abstract]   [Full Text] [Related]  

  • 14. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project.
    Bennett CL; Stinson TJ; Vogel V; Robertson L; Leedy D; O'Brien P; Hobbs J; Sutton T; Ruckdeschel JC; Chirikos TN; Weiner RS; Ramsey MM; Wicha MS
    J Clin Oncol; 2000 Aug; 18(15):2805-10. PubMed ID: 10920127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Of value: A discussion of cost, communication, and evidence to improve cancer care.
    Schickedanz A
    Oncologist; 2010; 15 Suppl 1():73-9. PubMed ID: 20237221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does evidence-based medicine really reduce costs?
    Kolodziej MA
    Oncology (Williston Park); 2011 Mar; 25(3):214, 218. PubMed ID: 21548463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of treatments for cancer in childhood.
    Barr RD; Feeny D; Furlong W
    Eur J Cancer; 2004 Jun; 40(9):1335-45. PubMed ID: 15177493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic evaluation of cancer treatments and programmes.
    Goddard M; Drummond M
    Eur J Cancer; 1991; 27(10):1191-6. PubMed ID: 1835583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.